Aduro Biotech, Inc. today announced the presentation of updated, interim safety and efficacy data from an ongoing Phase 1b clinical trial of its novel immunotherapy, CRS-207, in combination with standard of care chemotherapy in patients with unresectable malignant pleural mesothelioma . Of the 34 evaluable patients, disease control was observed in 94% , including 59% with partial responses and 35% experiencing stable disease following treatment with CRS-207 and chemotherapy.
